William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with Brinsupri, Arikayce, and TPIP have the potential to significantly increase Insmed’s valuation. The firm added that it believes the potential for a strong commercial launch of Brinsupri in the multi-blockbuster bronchiectasis indication will keep Insmed as a “must-own” name for investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Insmed price target raised to $145 from $121 at Stifel
- Insmed price target raised to $139 from $126 at Truist
- H.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential